Smallpox Vaccine & You
New Revenue Streams for Government Friends
The Hitler of 2022, Bill Gates, funds gain-of-function medical research. He then predicts an outbreak of an extinct killer since the 80s, smallpox. Then on November 4th, 2021, like on oracle, he warns about potential bio-terror attacks of smallpox at airports. (Daniel Horowitz. 2021).
Next up, Merck labs. They carry his narrative forward. Dangerous vials of smallpox could appear in labs. And like clockwork, they do. They materialize in their North Wales PA facility. Five vials labeled deadly smallpox sat in one of their freezers. How did they get there? No one knows, it's magic.
But the madness doesn't end there. As vaccines become the new norm since covid, the CDC does a one up. On June 4th, 2021, they approved an untested dangerous smallpox drug Tembexa (brincidofovir). The reason behind their decision,
“there have been longstanding concerns that the virus that causes smallpox, the variola virus, could be used as a bioweapon [gain-of-function alterations].”
Even though the drug
failed safety concerns,
causes severe adverse reactions
and, in some cases, death,
the FDA gives a green light (Daniel Horowitz. 2021).
And of all the companies in the game, who wins? None other than Emergent Biosolutions. A company tied to the Bill and Melinda Gates Foundation through the International Vaccine Institute.
They’re also an Operation Wrap Speed winner who had ties to the government long before Trump.
BARDA & Emergent
Since 2012, Emergent worked hand in hand with BARDA. Together, they turned facilities into pandemic response sites where they focused on pandemic flu. Over time they expanded their initiatives. They added Zika and Ebola virus into the mix (Fraiser Kansteiner. 2021).
With BARDA’s help, on December 8, 2016, they formed a one plus billion dollar deal for an Anthrax vaccine, BioThrax®. 29.4 million doses delivered to the Strategic National Stockpile (SNS) by September 2021. To guarantee their Anthrax monopoly, BARDA awarded them another contract. This time $1.6 billion for NuThrax on September 30, 2016. Even though the drug sits under EUA, the FDA adds it to the national stockpile (Burrows, 2016).
"Emergent believes these actions reflect the U.S. government’s continued assessment of anthrax as a high-priority threat and its firm commitment to protect the nation against bioterrorism,” said Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions. "We are pleased to be able to make meaningful contributions to helping the government execute its strategy to achieve its preparedness goals." (Burrows, 2016, p. 2)
To further waste American tax dollars, Trump rewards them with another contract in June 2020. Emergent receives $628 million for the production of COVID vaccines via Operation Wrap Speed (OWS).
Chimerix & Emergent
On June 2021, the FDA approved Chimerix’s smallpox vaccine TEMBEXA® (brincidofovir). With the Gates narrative in play, Emergent Biosolutions Inc (NYSE: EBS) made their move. On May 16, 2022 they bought exclusive world-wide rights of the drug $325 million (GLOBE NEWSWIRE. 2022).
A tax funded company ready to inject the American people and the world. An untested, unsafe drug awaits the veins of its victims. Brought to you by the FDA. A criminal cartel for sale, to the highest bidder.
5.1 Increased Risk for Mortality When Used for Longer Duration
5.2 Elevations in Hepatic Transaminases and Bilirubin
5.3 Diarrhea and Other Gastrointestinal Adverse Events
5.4 Coadministration with Related Products
5.5 Embryo-fetal Toxicity
5.6 Carcinogenicity
5.7 Male Infertility” (FDA, 2021, p. 1)
The effectiveness of TEMBEXA for the treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical (FDA, 2021, p. 2)
It’s not ethical to human trials, but it’s ethical to inject for profit. Logical thinking 101 no longer exists in the United States of America.
Godspeed, my friends. We’re going to need it. The roads are about to crumble.
Cites
Daniel Horowitz. 2021. “Horowitz: Are Elites Planning a COVID Repeat … with Smallpox?” News. TheBlaze. November 18, 2021.
Research, Center for Drug Evaluation and. 2021. “FDA Approves Drug to Treat Smallpox.” FDA, September.
Fraiser Kansteiner. 2021. “Emergent, Partnered with COVID-19 Vaccine Players J&J and AstraZeneca, Works 24/7 to Scale up Doses.” FiercePharma. February 17, 2021.
Christopher Rowland and Laurie McGinley. 2021. “Merck Will Help Make Johnson & Johnson Coronavirus Vaccine as Rivals Team up to Help Biden Accelerate Shots.” Washington Post, March 3, 2021.
GLOBE NEWSWIRE. 2022. “Emergent BioSolutions to Acquire from Chimerix Its Exclusive Worldwide Rights to TEMBEXA® (Brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages.” BioSpace. May 16, 2022.
Burrows, Robert G. 2016. “FOR IMMEDIATE RELEASE.” Emergent Biosolutions.
FDA. 2021. “TEMBEXA®.”